u/discount_math_dm

this is the arithmetic nobody does. the discount is real and so is losing chargeback rights and so is the gas. three numbers, and people only ever hold one.

Switched between two compounded preparations and the concentration on the label was different. Redid the arithmetic on paper before drawing anything.

This is the fifth "should I go up" post today and they are all welcome — but no member here can answer it for you.

dexa_twice_yearly is right that the two molecules are not interchangeable. There is no published conversion and the ones circulating are invented.

the crypto discount is real and so is losing chargeback rights. those are the two facts and people only ever quote the first.

triple agonist — GLP-1, GIP and glucagon, and the glucagon arm is the new part

The phase 2 readout ran to 48 weeks in a few hundred participants with a slow escalation. Both the size and the duration matter when people quote the headline number.

Correcting my own comment above: that figure was the 36-week interim, not the 48-week endpoint.

Correction: TRIUMPH is the phase 3 programme.

Adding the standing caveat: none of this is approved anywhere and research material is not for human use.

Push back: quoting the phase 2 headline as an expected outcome is not a fair reading of a small trial with wide intervals.

shortage status changes and the whole arrangement changes with it

What did the tolerability table look like at that dose?

Rate quotes expire because the underlying rate moves. A short expiry is ordinary; urgency about your decision is a separate signal and should be read separately.

the memo field matters on the chains that use one

Disagree. "More receptors means more effect" is not how any of this works and the trial data does not support the linear story.

What step are you on and how long have you been there?

Correction to my own post above — I said 5mg and I have been on 7.5mg since the spring. Same argument, wrong number.

Not sure that follows. You went up a step and changed your training in the same fortnight.

the four-week step schedule is the label, not folklore

Push back: daily dosing is not automatically better adherence. It is a different failure mode, not a solved problem.

That is body weight change, not fat mass. The trials report the first and people quote it as the second.

What is the waist doing? That is usually the number still moving during a scale stall.

the four-week step schedule is the label, not folklore

the energy-expenditure story is mechanistically interesting and clinically unproven

Yes. I stepped to 12.5 because the calendar said so, not because anything needed fixing, and I regretted it for a fortnight.

The step schedule question, answered properly, because it comes up weekly.

The label sets a minimum interval of four weeks between increases. That is a floor on how fast you may go, and it exists because tolerability, not efficacy, is what limits most people. There is nothing in the pharmacology that says you must increase at four weeks, or at eight, or ever.

What decides it in practice is whether the effect you want is still there. If appetite is quiet and the trend is going the right way, the dose is doing its job. If both have genuinely gone flat for six weeks or more, that is a conversation worth having with someone who knows your history.

Glucagon receptor agonism is associated with increased energy expenditure and with hepatic effects. That is a mechanistic story with strong preclinical support and limited phase 2 human data.

Cosigning the escalation point. Almost every difficult report on this board is from somebody who went up quickly.

This. Modmail first is not bureaucracy; it stops individual cases turning into a public pile-on.

SURMOUNT-1 ran 72 weeks with the top arm around 21% mean body weight change. SURPASS is the diabetes programme and reports glycaemic endpoints, so quoting the two interchangeably is a category error.

a telehealth intake that asks nothing has told you what it is

Push back: an unconfirmed transaction is not a missing payment. Wait for confirmations before escalating.

Read the ranking formula out of scepticism and reproduced the ordering in a spreadsheet. It does what it says.

Compounded preparations are not approved products and carry no bioequivalence claim. That is a statement about regulatory category, not about quality.

Analytically this is a small-molecule identity and purity problem, not a peptide one. The methods, the impurity classes and the reference standards are all different.

the label on a compounded vial is a legal document, read it

Adding one thing — ask for the facility name. Most will give it, and the ones that will not have answered you.

escrow arrangements are rare and worth asking about

Submissions older than a year are archived: readable, linkable, and closed to new comments. That keeps a three-year-old thread from being reopened with a reply nobody will see in context.

evidence rules are strict here on purpose